Testing effectiveness (Phase 2)UnknownNCT05799820
What this trial is testing
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
Who this might be right for
Colorectal Carcinoma
Qilu Pharmaceutical Co., Ltd. 60